Carboplatin-associated Cranial Neuropathy

Overview

Journal Neuroophthalmology

Specialty Neurology

Date 2018 Sep 28

PMID 30258477

Citations 2

Authors

Shanlee M Stevens

Collin M McClelland

John E Trusheim

Michael S Lee

Affiliations

Soon will be listed here.

Abstract

Carboplatin is a platinum-based chemotherapeutic agent used for the treatment of many solid tumors. Peripheral neuropathy is a common side effect; but, to our knowledge, ocular motor cranial neuropathies have not been reported in the literature. We describe a case of persistent third and fourth nerve palsies after systemic administration of intra-arterial carboplatin for glioblastoma multiforme. Neither nerve regained function after carboplatin was stopped.

Citing Articles

A phenotypic screening platform for chronic pain therapeutics using all-optical electrophysiology.

Liu P, Zhang H, Werley C, Pichler M, Ryan S, Lewarch C Pain. 2023; 165(4):922-940.

PMID: 37963235 PMC: 10950549. DOI: 10.1097/j.pain.0000000000003090.

Isolated Pyridoxine Deficiency Presenting as Peripheral Neuropathy Post-chemotherapy.

Sawhney A, Singhal S, Patel R Cureus. 2022; 14(7):e26725.

PMID: 35967133 PMC: 9363682. DOI: 10.7759/cureus.26725.

References

Addington J, Freimer M . Chemotherapy-induced peripheral neuropathy: an update on the current understanding. F1000Res. 2016; 5. PMC: 4920214. DOI: 10.12688/f1000research.8053.1. View

Schwaninger M, Patt S, Henningsen P, Schmidt D . Spinal canal metastases: a late complication of glioblastoma. J Neurooncol. 1992; 12(1):93-8. DOI: 10.1007/BF00172461. View

Angelov L, Doolittle N, Kraemer D, Siegal T, Barnett G, Peereboom D . Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience. J Clin Oncol. 2009; 27(21):3503-9. PMC: 2717756. DOI: 10.1200/JCO.2008.19.3789. View

Bryan P . CSF seeding of intra-cranial tumours: a study of 96 cases. Clin Radiol. 1974; 25(3):355-60. DOI: 10.1016/s0009-9260(74)80168-6. View

Johnstone T, Park G, Lippard S . Understanding and improving platinum anticancer drugs--phenanthriplatin. Anticancer Res. 2014; 34(1):471-6. PMC: 3937549. View

Theodotou C, Shah A, Hayes S, Bregy A, Johnson J, Aziz-Sultan M . The role of intra-arterial chemotherapy as an adjuvant treatment for glioblastoma. Br J Neurosurg. 2014; 28(4):438-46. DOI: 10.3109/02688697.2013.877122. View

Park H, Guy J . Sixth nerve palsy post intravitreal bevacizumab for AMD: a new possibly causal relationship and complication?. Binocul Vis Strabismus Q. 2008; 22(4):209. View

Fakhrai N, Czech T, Diekmann K, Fazeny-Dorner B, Birner P, Hainfellner J . Glioblastoma with spinal seeding. Strahlenther Onkol. 2004; 180(7):455-7. DOI: 10.1007/s00066-004-1293-3. View

Momeni M, Veras L, Zakashansky K . Bevacizumab-induced transient sixth nerve palsy in ovarian cancer: A case report. Asia Pac J Clin Oncol. 2013; 12(1):e196-8. DOI: 10.1111/ajco.12129. View

10.

Grisold W, Cavaletti G, Windebank A . Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol. 2012; 14 Suppl 4:iv45-54. PMC: 3480245. DOI: 10.1093/neuonc/nos203. View

11.

Argyriou A, Bruna J, Marmiroli P, Cavaletti G . Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol. 2011; 82(1):51-77. DOI: 10.1016/j.critrevonc.2011.04.012. View

12.

Dasari S, Tchounwou P . Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014; 740:364-78. PMC: 4146684. DOI: 10.1016/j.ejphar.2014.07.025. View

13.

Avan A, Postma T, Ceresa C, Avan A, Cavaletti G, Giovannetti E . Platinum-induced neurotoxicity and preventive strategies: past, present, and future. Oncologist. 2015; 20(4):411-32. PMC: 4391771. DOI: 10.1634/theoncologist.2014-0044. View

14.

Amptoulach S, Tsavaris N . Neurotoxicity caused by the treatment with platinum analogues. Chemother Res Pract. 2012; 2011:843019. PMC: 3265255. DOI: 10.1155/2011/843019. View